Madrigal Pharmaceuticals, Inc. (MDGL)
537.19
-2.84
(-0.53%)
USD |
NASDAQ |
Sep 01, 12:59
Madrigal Pharmaceuticals Cash from Operations (TTM) : -197.72M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -197.72M |
| March 31, 2026 | -268.10M |
| December 31, 2025 | -189.55M |
| September 30, 2025 | -160.58M |
| June 30, 2025 | -307.41M |
| March 31, 2025 | -395.31M |
| December 31, 2024 | -455.57M |
| September 30, 2024 | -431.02M |
| June 30, 2024 | -448.96M |
| March 31, 2024 | -389.32M |
| December 31, 2023 | -324.23M |
| September 30, 2023 | -302.81M |
| June 30, 2023 | -276.96M |
| March 31, 2023 | -259.01M |
| December 31, 2022 | -224.86M |
| September 30, 2022 | -214.39M |
| June 30, 2022 | -200.88M |
| March 31, 2022 | -190.40M |
| December 31, 2021 | -183.92M |
| September 30, 2021 | -190.81M |
| June 30, 2021 | -193.11M |
| March 31, 2021 | -170.48M |
| December 31, 2020 | -157.56M |
| September 30, 2020 | -114.90M |
| June 30, 2020 | -78.37M |
| Date | Value |
|---|---|
| March 31, 2020 | -65.65M |
| December 31, 2019 | -41.62M |
| September 30, 2019 | -35.61M |
| June 30, 2019 | -29.52M |
| March 31, 2019 | -23.34M |
| December 31, 2018 | -25.51M |
| September 30, 2018 | -25.19M |
| June 30, 2018 | -24.90M |
| March 31, 2018 | -27.19M |
| December 31, 2017 | -22.32M |
| September 30, 2017 | -21.65M |
| June 30, 2017 | -25.94M |
| March 31, 2017 | -20.94M |
| December 31, 2016 | -17.61M |
| September 30, 2016 | -13.42M |
| June 30, 2016 | 30.28M |
| March 31, 2016 | 15.20M |
| December 31, 2015 | -3.142M |
| September 30, 2015 | -21.26M |
| June 30, 2015 | -74.29M |
| March 31, 2015 | -77.43M |
| December 31, 2014 | -78.92M |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Exelixis, Inc. | 1.183B |
| Karyopharm Therapeutics, Inc. | -65.35M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |